PUMA BIOTECHNOLOGY, INC.
No SEC Form 4 filings for $PBYI in the last 30 days.
See all $PBYI insider activity →Several biotech stocks reached 52-week highs on October 9, 2026. Humana (HUM) rose 11% to $456.50, driven by improved Medicare Advantage ratings. Puma Biotechnology (PBYI) gained 3% to $10.10, while AbbVie (ABBV) hit $274.94. Moderna (MRNA) surged 14% to $225 after positive clinical trial results. AVITA Medical (RCEL) climbed to $13.71, reporting 18% revenue growth in Q2 2026.
On September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
Cesano Alessandra sold 62,150 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $9.12 ($0.57M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PBYI (PUMA BIOTECHNOLOGY, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PBYI coverage spans earnings, financial news and market movers.
Positive catalyst from new trial data and drug licensing could boost near‑term demand.
Pipeline progress and licensing deals provide upside potential.
Insider sale reduces insider ownership but is pre‑arranged, likely limited price impact.
Guidance raise and improved demand metrics for NERLYNX increase near-term earnings visibility, while royalty-rate and trade-policy risks cap upside.
Guidance raises near-term earnings visibility while amended alisertib trial dosing and enrollment timing push catalysts into Q3-Q4.
AlphAI scores every news story that mentions PBYI with an AI model for sentiment and relevance, and aggregates insider trades from PUMA BIOTECHNOLOGY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Several biotech stocks reached 52-week highs on October 9, 2026. Humana (HUM) rose 11% to $456.50, driven by improved Medicare Advantage ratings. Puma Biotechnology (PBYI) gained 3% to $10.10, while AbbVie (ABBV) hit $274.94. Moderna (MRNA) surged 14% to $225 after positive clinical trial results. AVITA Medical (RCEL) climbed to $13.71, reporting 18% revenue growth in Q2 2026.
3 min readOn September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
2 min readCesano Alessandra sold 62,150 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $9.12 ($0.57M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readPuma Biotechnology (PBYI) reported Q2 2026 revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million. GAAP net income was $8.2 million ($0.16/share). The company raised full-year net product revenue guidance to $205 million to $209 million and net income to $17 million to $20 million, while lowering royalty guidance to $19 million to $22 million.
7 min readPuma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.
7 min readPUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, Calif., Aug. 6, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
7 min readPUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. pbyi20260613_8k.htm false 0001401667 0001401667 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report
2 min readPuma Biotechnology closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million. Despite improving net profit margins, analysts forecast an 11.2% annual decline in earnings over the next three years, contrasting sharply with its strong multi-year growth. The company's heavy reliance on its single product, NERLYNX, and its low P/E ratio compared to peers, reflect investor caution regarding future profitability and revenue forecasts.
5 min readIronwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
5 min readPuma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
2 min read
